Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults
-
- Yoseph Caraco
- Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
-
- Gordon E. Crofoot
- Crofoot Research Center, Inc., Houston, TX
-
- Pablo Andres Moncada
- Department of Internal Medicine, Infectious Disease Service, Fundación Valle del Lili, Cali, Colombia
-
- Anna Nikolaevna Galustyan
- Saint Petersburg State Pediatric Medical University, Saint Petersburg, Russia
-
- Dany Badibanga Musungaie
- Jongaie Research, Gauteng, South Africa
-
- Brendan Payne
- Departments of Infectious Diseases and Medical Virology, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK
-
- Evgeniy Kovalchuk
- Medical Research Institute LLC, Saint Petersburg, Russia
-
- Antonio Gonzalez
- Advanced Research for Health Improvement LLC, Immokalee, FL
-
- Michelle L. Brown
- Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ
-
- Angela Williams-Diaz
- Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ
-
- Wei Gao
- Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ
-
- Julie M. Strizki
- Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ
-
- Jay Grobler
- Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ
-
- Jiejun Du
- Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ
-
- Christopher A. Assaid
- Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ
-
- Amanda Paschke
- Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ
-
- Joan R. Butterton
- Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ
-
- Matthew G. Johnson
- Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ
-
- Carisa De Anda
- Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ
Journal
-
- NEJM Evidence
-
NEJM Evidence 1 (2), 2022-01-25
Massachusetts Medical Society
- Tweet
Details 詳細情報について
-
- CRID
- 1360294663749520512
-
- ISSN
- 27665526
-
- Data Source
-
- Crossref